These data indicate that ropivacaine inhibits the occurrence and development of colorectal cancer by inhibiting the expression of itgb1 and phosphorylation of its downstream pathway, thus playing a role in tumor inhibition. This evidence concerns the gene ITGB1 and neoplasm.